Literature DB >> 9792133

5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death.

K M Anderson1, T Seed, M Vos, J Mulshine, J Meng, W Alrefai, D Ou, J E Harris.   

Abstract

BACKGROUND: Products of the arachidonic acid-metabolizing enzyme, 5-lipoxygenase, stimulate the growth of several cell types. Selective inhibitors of the enzyme, including SC41661A and MK886, reduce PC-3 prostate cell proliferation. With continued culture, cells die, but the mode of death, necrotic or nonnecrotic, has not been established.
METHODS: Flow cytometry, laddering after agarose electrophoresis of DNA from inhibitor-treated cells, and light and electron microscopy were employed to examine the type of death in PC-3 prostate cells cultured with either 5-lipoxygenase inhibitor.
RESULTS: The inhibitors induced nonnecrotic, programmed cell death. SC41661A-treated cells exhibited "foamy," vacuolated cytoplasm and mitochondria with disrupted cristae and limiting membranes, while some cells contained numerous polysomes and extended hypertrophic Golgi and secretory cisternal networks. A proportion of the treated cells detached and the nuclei of these cells were characteristic of type 1 "apoptotic" programmed cell death. MK886, a 5-lipoxygenase-inhibitor with a different mechanism of action, induced nonnecrotic changes largely confined to the cytoplasm, most consistent with type 2 "autophagic" programmed cell death. In preliminary studies of mechanism, we demonstrated that PC-3 cells express mRNA for 5-lipoxygenase and for 5-lipoxygenase-activating protein. The less active inhibitor, SC45662 neither reduced proliferation nor induced DNA laddering. The antioxidant, N-acetyl-l-cysteine but not butylated hydroxy toluene or alpha tocopherol, partially reduced the inhibition of proliferation from SC41661A.
CONCLUSIONS: SC41661A and MK886 inhibit PC-3 cell proliferation and induce a form of type 1 or type 2 programmed cell death, respectively. PC-3 cells contain messenger RNA for 5-lipoxygenase and 5-lipoxygenase-activating proteins. Drug-induced changes included altered redox potential, inferred from the increased survival due to the antioxidant and glutathione precursor, N-acetyl-l-cysteine. PC-3 cells are an appropriate model for studying the mechanism responsible for 5-lipoxygenase inhibitor-induced cellular suicide.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792133     DOI: 10.1002/(sici)1097-0045(19981101)37:3<161::aid-pros5>3.0.co;2-d

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  15 in total

1.  Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon.

Authors:  Sivalokanathan Sarveswaran; Vijayalakshmi Thamilselvan; Chaya Brodie; Jagadananda Ghosh
Journal:  Biochim Biophys Acta       Date:  2011-07-30

2.  Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.

Authors:  Naoko Kobayashi; R James Barnard; Susanne M Henning; David Elashoff; Srinivasa T Reddy; Pinchas Cohen; Pak Leung; Jenny Hong-Gonzalez; Stephen J Freedland; Jonathan Said; Dorina Gui; Navindra P Seeram; Laura M Popoviciu; Dilprit Bagga; David Heber; John A Glaspy; William J Aronson
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

3.  15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma.

Authors:  S B Shappell; W E Boeglin; S J Olson; S Kasper; A R Brash
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

4.  Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma.

Authors:  S B Shappell; S Manning; W E Boeglin; Y F Guan; R L Roberts; L Davis; S J Olson; G S Jack; C S Coffey; T M Wheeler; M D Breyer; A R Brash
Journal:  Neoplasia       Date:  2001 Jul-Aug       Impact factor: 5.715

5.  Analysis of a nucleotide-binding site of 5-lipoxygenase by affinity labelling: binding characteristics and amino acid sequences.

Authors:  Y Y Zhang; T Hammarberg; O Radmark; B Samuelsson; C F Ng; C D Funk; J Loscalzo
Journal:  Biochem J       Date:  2000-11-01       Impact factor: 3.857

6.  Inhibition of 5-lipoxygenase selectively triggers disruption of c-Myc signaling in prostate cancer cells.

Authors:  Sivalokanathan Sarveswaran; Debrup Chakraborty; Dhananjay Chitale; Rosalie Sears; Jagadananda Ghosh
Journal:  J Biol Chem       Date:  2014-12-24       Impact factor: 5.157

7.  Expression of 5-lipoxygenase in pulmonary artery endothelial cells.

Authors:  Ying-Yi Zhang; Jennifer L Walker; Annong Huang; John F Keaney; Clary B Clish; Charles N Serhan; Joseph Loscalzo
Journal:  Biochem J       Date:  2002-01-15       Impact factor: 3.857

8.  Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer.

Authors:  Manish I Patel; Jaskirat Singh; Marzieh Niknami; Caroline Kurek; Mu Yao; Sasa Lu; Fiona Maclean; Nicholas J C King; Michael H Gelb; Kieran F Scott; Pamela J Russell; John Boulas; Qihan Dong
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

9.  Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.

Authors:  Sarah E Kleinstein; Laura Heath; Karen W Makar; Elizabeth M Poole; Brenna L Seufert; Martha L Slattery; Liren Xiao; David J Duggan; Li Hsu; Karen Curtin; Lisel Koepl; Jill Muehling; Darin Taverna; Bette J Caan; Christopher S Carlson; John D Potter; Cornelia M Ulrich
Journal:  Genes Chromosomes Cancer       Date:  2013-02-12       Impact factor: 5.006

10.  OXER1, a G protein-coupled oxoeicosatetraenoid receptor, mediates the survival-promoting effects of arachidonate 5-lipoxygenase in prostate cancer cells.

Authors:  Sivalokanathan Sarveswaran; Jagadananda Ghosh
Journal:  Cancer Lett       Date:  2013-05-02       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.